Embedded Files
Our Pipeline
Our Pipeline
Metreleptin for Anorexia Nervosa
Metreleptin for Anorexia Nervosa
STATUS: Pre-IND/Manufacturing Development
STATUS: Pre-IND/Manufacturing Development
Our lead program focuses on metreleptin as a hormone replacement therapy for anorexia nervosa (AN). Clinical evidence from European research centers shows rapid improvement in depression, anxiety, and cognitive flexibility within days of treatment.
New Formulations
New Formulations
STATUS: Development Planning
STATUS: Development Planning
We're developing improved metreleptin formulations with:
Enhanced stability
Optimized dosing regimens
Improved patient convenience
Potential for extended release
Future Programs
Future Programs
STATUS: Research
STATUS: Research
Expanded Indications: Applications for atypical anorexia and eating disorder-associated depression
Amenorrhea Treatment: Addressing hormone-related menstrual disruption in patients with eating disorders and hypothalamic amenorrhea
As a public benefit corporation, Zula is committed to making these treatments accessible and affordable for patients with eating disorders.
As a public benefit corporation, Zula is committed to making these treatments accessible and affordable for patients with eating disorders.
Page updated
Report abuse